These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 15752679

  • 1. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR, Pressler T, Koch C, Høiby N.
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [Abstract] [Full Text] [Related]

  • 2. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR, Pressler T, Hoiby N, Johansen HK.
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [Abstract] [Full Text] [Related]

  • 3. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
    Pirzada OM, McGaw J, Taylor CJ, Everard ML.
    J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
    [Abstract] [Full Text] [Related]

  • 4. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR, Pressler T, Høiby N.
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [Abstract] [Full Text] [Related]

  • 5. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK.
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [Abstract] [Full Text] [Related]

  • 6. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, Meyer P, Pressler T, Lindblad A, Scandinavian CF Study Consortium (SCFSC).
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [Abstract] [Full Text] [Related]

  • 7. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S.
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [Abstract] [Full Text] [Related]

  • 8. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
    De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M.
    J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
    [Abstract] [Full Text] [Related]

  • 9. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
    Guillot M, Amiour M, El Hachem C, Harchaoui S, Ribault V, Paris C.
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
    [Abstract] [Full Text] [Related]

  • 10. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R, Champion A, Reid DW.
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [Abstract] [Full Text] [Related]

  • 11. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C, Hall M, Conway S, Peckham D, Denton M.
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [Abstract] [Full Text] [Related]

  • 12. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.
    Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Høiby N.
    J Cyst Fibros; 2006 Jan; 5(1):9-15. PubMed ID: 16412706
    [Abstract] [Full Text] [Related]

  • 13. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O.
    APMIS Suppl; 2003 Jan; (116):1-47. PubMed ID: 14692154
    [Abstract] [Full Text] [Related]

  • 14. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL.
    Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
    [Abstract] [Full Text] [Related]

  • 15. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
    Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N.
    Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary infection in mild variant cystic fibrosis: implications for care.
    Lording A, McGaw J, Dalton A, Beal G, Everard M, Taylor CJ.
    J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904
    [Abstract] [Full Text] [Related]

  • 17. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
    Kabra SK, Pawaiya R, Lodha R, Kapil A, Kabra M, Vani AS, Agarwal G, Shastri SS.
    J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB, Touw DJ, Heijerman HG.
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [Abstract] [Full Text] [Related]

  • 19. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
    Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N.
    Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
    Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K.
    J Pediatr; 2001 May; 138(5):699-704. PubMed ID: 11343046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.